about us

 

Press Release

VIB and KU Leuven announce new spin-off

Augustine Therapeutics to fight neuromuscular diseases

 

Belgium, December 16, 2019 – Today, VIB and KU Leuven present a new venture, Augustine Therapeutics, with the mission to develop innovative therapeutics for patients suffering from Charcot-Marie-Tooth disease. Augustine raises a seed-round of 4.2 million euro with V-Bio Ventures, PMV, Advent France Biotechnology, Gemma Frisius Fund and VIB.

Therapeutics for neuromuscular  diseases ​

 

Augustine Therapeutics focuses on the discovery and development of innovative medicines to benefit patients suffering from Charcot-Marie-Tooth disease (CMT) and other neuromuscular diseases. The newly formed company is rooted in the ground-breaking research at VIB and KU Leuven and supported by V-Bio Ventures, PMV, Advent France Biotechnology and Gemma Frisius Fund. ​